中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
机构
采集方式
内容类型
发表日期
学科主题
筛选

浏览/检索结果: 共5条，第1-5条 帮助

条数/页： 排序方式：
Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma-evaluation of anti-tumor efficacy and brain distribution 期刊论文  OAI收割
TRANSLATIONAL CANCER RESEARCH, 2021, 卷号: 10
作者:  Yu, Haifeng;  Kong, Haiying;  Li, Cong;  Dong, Xiaowu;  Wu, Yizhe
  |  收藏  |  浏览/下载：30/0  |  提交时间：2021/08/31
Activation of unfolded protein response overcomes Ibrutinib resistance in diffuse large B-cell lymphoma 期刊论文  OAI收割
ACTA PHARMACOLOGICA SINICA, 2020, 页码: 10
作者:  Zhang, Xiao-tuan;  Hu, Xiao-bei
  |  收藏  |  浏览/下载：98/0  |  提交时间：2020/12/24
Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors 期刊论文  OAI收割
ACTA PHARMACOLOGICA SINICA, 2020, 卷号: 41, 期号: 3, 页码: 415-422
作者:  Lai, Meng-zhen;  Song, Pei-ran;  Dou, Dou;  Diao, Yan-yan;  Tong, Lin-jiang
  |  收藏  |  浏览/下载：20/0  |  提交时间：2020/07/01
Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation 期刊论文  OAI收割
ONCOTARGET, 2016, 卷号: 7, 期号: 43, 页码: 69760-69769
作者:  Wang, Aoli;  Yan, Xiao-E;  Wu, Hong;  Wang, Wenchao;  Hu, Chen
收藏  |  浏览/下载：87/0  |  提交时间：2017/11/21
Breakthrough cancer medicine and its impact on novel drug development in China:report of the US Chinese Anti-Cancer Association (USCACA) and Chinese Society of Clinical Oncology (CSCO) Joint Session at the 17th CSCO Annual Meeting 期刊论文  OAI收割
Chinese Journal of Cancer, 2014, 卷号: 33, 期号: 12, 页码: 620
作者:  Luo Feng Roger;  Ding Jian;  Chen Helen X;  Liu Hao;  Fung Mancheong
  |  收藏  |  浏览/下载：15/0  |  提交时间：2020/07/01